The emergence of biotechnology is one of the most important changes in the health innovation systems. This paper discusses the rationale that has supported the public policies oriented to boost health biotechnology development in Brazil during 2004 and 2014. Based on a thorough revision of policy documents and on an extensive fieldwork, the study highlights the accumulative path followed by the Brazilian public policies. This research shows how these policies followed an uneven accumulative path were several rationales cohabited integrating explicit and implicit policies. Finally, the boundaries of policy action are discussed, stressing two critical dimensions that delimit the scope of policy action: i) the change of policy orientation and rationale, ii) that pose new governance's challenges, which, in turn require new coordination with other implicit policies.
Among them, the Brazilian case has been regarded as one of the new players in the production of healthcare solutions based on biotechnology research (Rezaie et al. 2008 ).
Brazil has a small but significant amount of firms devoted to human health biotechnologies as well as a large accumulation of scientific capabilities in this field (Torres Freire 2014) . During the period 2004-2014, the Brazilian innovation and productive policies stressed the strategic relevance of biotechnology as a tool to deal with national health challenges as well as to promote new knowledge based activities.
Based on international experiences and in the evolution of the Brazilian health biotech innovation policies, this paper revisits earlier analysis of the public policies devoted to health biotech in Brazil (Bianchi 2013a ) discussing the policy rationale. The paper deals with two main question: What has the rationale of biotech policy been? Has the theoretical basis of these policy rationales changed?
The general hypothesis states that several rationales cohabit during the period [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] supporting different objectives and instruments. Even though this process has been erratic, it allows the emergence of adequate institutional solutions to deal with some of the most relevant challenges of the Brazilian health biotechnology system.
The second section presents a brief revision of the theoretical basis of the Brazilian biotechnology policy rationale. The general hypothesis states that this rationale is based on theoretical ideas built on the experiences of developed countries, mostly built on the United State (US) biotechnology industry. In section three the Brazilian Health Biotechnology Innovation System (BHBIS) is analyzed contrasting its most significant features to some stylized facts of the U.S. health biotechnology innovation system. This comparison allows stressing the intermediate mechanisms operating in each case and particularly, to point out the relative importance of market and state mechanisms. Finally, the conclusions discuss the boundaries of public policy action, by analyzing how some systemic features delimit the potential action of policies.
A POLICY RATIONALE: WHAT ARE THE THEORETICAL ASSUMPTIONS BEHIND POLICY PROGRAMS?
From a static point of view, a biotechnology health system is defined as a web of relationship in which different types of agents and institutions participate in working on the biotechnology health development process. It involves government agencies in charge of public policy design and research funding, research institutions, public and private firms fully or partially devoted to biotechnology, Complementing this vision from a dynamic approach implies the analysis of how this web of relationship changes through time, varying its size and functions (Dodgson et al. 2008) . The aim of this paper is to discuss how a specific feature of the Brazilian health biotechnology innovation systems changed in the period [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] . It refers to the public policies oriented to promote the health biotechnology development and, specifically to the rationale of these policies. The general hypothesis states that national public policies oriented to boost the development of health biotechnology in Brazil has been based on the expectation to reproduce some stylized patters of the U.S. experience.
HUMAN HEALTH BIOTECHNOLOGY: AND OPERATIVE DEFINITION
Although there are several debates about what modern biotech is and what is not, there are more coincidences than differences related to the biotechnology technical definition (Fonseca 2009; Orsenigo 1989; Pisano 2006; Hopkins et al. 2007) . Regarding the coincidences, biotechnology is defined in this paper as a body of knowledge and a comprehensive set of procedures and technologies that analyses the attributes of the cells allowing the molecules, DNA and proteins to create or modify products or processes for specific uses with various applications.
Even using a general definition of biotechnology, several authors contend that there is not an evident definition of biotechnology in the health sector, because of the variety of biotechnological, chemical and bioinformatics techniques that are introduced into health related industries. In this regard, there are different operative definitions, which have been proposed according to the specific objective of each research, but there is not a consensual definition. Taking into account this discussions, this work follows a wide definition of health biotechnology that embraces the discovery of therapeutic agents that are used in healthcare as well as rational drug design, drug delivery systems, and manufacturing of drugs, serum, vaccine and others biotech developed products (Niosi & Reid 2007 ).
THE EVOLUTION OF MODERN HEALTH BIOTECHNOLOGY INDUSTRY: FROM THEORY TO POLICY MODELS
The history of the upsurge of biotech in the industrial health complex, especially in the pharmaceutical industry, has been widely exposed by several authors. This history has always been related to the experienced of developed countries, mainly U.S. Rather than recalling the history once again, this section is focused on three stylized facts of the widespread theoretical explanations on this process (Bianchi 2013a ii) While small dedicated biotech firms (DBF) emerge from science-production relationships, the incumbent big pharmaceutical firms follow different diversification strategies;
iii) The market mechanisms functioning works under a new institutional dynamic characterized by venture financial systems and intellectual property right (IPR) regulation.
Several authors stressed that the advent of modern biotechnology creates a new knowledge basis has been changing the drug innovation process (Gadelha 1990; McKelvey et al. 2004; Pammolli et al. 2011) . This change has happened while new linkages between research organizations and firm arose.
The development process of new therapeutic solutions requires strong linkages with scientific research (Brännback et al. 2009; McMillan et al. 2000; Kneller 2010 ). It shows a systemic dynamic where the scientific research activities influence in the goods and services health production while a growing influence of the industrial criteria in the scientific production is perceived (Orsenigo 1989; Pisano 2006) . It implies successive ramification of knowledge, from some general questions to emerge new specific hypothesis oriented to solve the development of a new drug for a new problem. The emergence of new problems is the results of the new discovery process in a successive solved problem chain (Orsenigo et al. 2001 ).
These changes boosted the appearance of new small and medium enterprises (SMEs) devoted to biotechnology creating different inter-firm relationships and different business models (Mangematin et al. 2003; Audretsch & Feldman 2003) . While the biotechnology health innovations emerge from SMEs and research centers, the big pharmaceutical firms adopted different strategies of diversification of the technological basis and product portfolio (Mittra 2007; Gutman & Laravello 2010) -in the initial stages-a strategy of wait and see to know the potential impact of the new emergent technologies (Hopkins et al. 2007 ).
On the other hand, at the same time that new firms entering in the market with a significant impact on the industrial structure, it is possible to observe a market concentration process led by the big firms. This process was promoted by market and institutional factors, but mainly by the structural features that are inherent to the health related industry. It has traditionally been a monopoly or oligopoly industry. In the case of pharmaceutical, the market works as an oligopoly segmented according to different therapeutic classes. Moreover, it is a market where the main products -ethical medicines-have low price elasticity, new firms find high barriers to entry (Caravaglia et al. 2006) Fronteiras Finally, all these transformations were accompanied by institutional changes creating a "market of ideas" through venture financial systems and intellectual property right regulation (Pisano 2006; Coriat et al. 2003) . Within this general landscape, a singular case is India. This is a national case which has been studied from the role of policies, its evolution, supporting actors and rationale (Ahn et al. 2012; Watkins et al. 2015; Reid & Ramani 2012; Ramani 2002) . These works stress the significance of the State's role in the Indian biopharmaceutical development, and how it was linked to a national strategy of gradual learning to became a global player in the biopharmaceutical market (Kale & Huzair 2015) .
Considering this background, the general hypothesis of this paper states that many features of the U.Ss health biotechnology system have been taken as a policy model in the Brazilian public policies oriented to promoted health biotechnology. It is particularly clear through the relevance given in the national explicit policies to create new dedicated biotechnology firms (DBF) and to boost patents of new molecules through university-firm collaboration agreements (Governo Federal 2007 & 2008 .
These policy objectives was presented almost as the normal way to develop commercial health biotechnology. However, at the same time, public effort were also oriented to boost the national pharmaceutical industry (Palmeira et al. 2012; Pimentel et al. 2013) .
In this point it is worth revisited the concept of implicit and explicit innovation policies (Herrera 1973; Galhardi 1994) . The later refer to scientific, technological, innovation or industrial policies which explicitly pursue an effect on the biotechnology development. On the other hand, the implicit policies could be any other public policy that implicitly affect the biotechnology development.
Typical examples are macroeconomic policies which affect, in one or another sense, the agents' decisions; i.e. the investment decision. In the case of the Brazilian health biotechnology, the more important implicit policy is the national health policy, which regulate the demand and delivery of most health service in Brazil. The universal healthcare system is one of the most relevant social pacts in the Brazilian society after the democracy recovery (Vargas 2009 The second hypothesis of this paper states that the Brazilian health biotechnology policies have been incorporated new policy models both from developed and developing countries. Many of these changes implied a growing concern with demand side policies and public private productive agreement rather than the earlier concern with firm creation and intellectual property rights.
The analysis of the BHBIS is conducted in a comparative and dynamics way. In this regard, 
THE BRAZILIAN HEALTH BIOTECH SYSTEM
The economical and policy features of health biotechnologies in Brazil has been widely studied during the last 30 years ( (Capanema et al. 2008; Vargas & Bianchi 2013) . In this situation, Brazilian biotechnological policies, both form innovation and industrial side as well as form the health side, pointed out the great challenge to take the advantage of biotechnology to boost national production. Recently, some big national firms, which had followed a strategy of "wait and see", are investing in new plants, incorporating biotechnology technicians' teams and production project in this area (Vargas 2009 ). In addition, new public private agreements have been carried out pursuing an increase in national production (Vargas & Bianchi 2013) .
Regarding the creation and development of DBF, earlier works stressed that the biotech On another hand, the Brazilian State is a key actor of the BHBIS. It not only acts as a policy maker and regulator. Indeed the State acts as healthcare services provider, drug producer and buyer.
Particularly, the role of public laboratories both in R&D and production activities is one of the basis of the BHBIS (Costa et al. 2014 ).
Comparing figure 1 and 2, the BHBIS presents the same mains actors as the US biotech system. Nevertheless, there are clear differences in the development of capital markets and IPR regime.
This does not imply that the BHBIS does not have financial instruments, but they are mostly concentrated on the public agencies. In Brazil, even the ventures capitals funds are composed by state owned firms that operate in private regime. Moreover, the other institutions that compose the BHBIS do not bear great "anatomic" differences when compared to US's. The differences are mostly found on the operation of the system rather than on its composition.
As Figure 2 shows, the BHBIS presents a different level of development (size of grey area) in each of their actors and a relatively weak development in the linkages among the agents. The central circles expose the dynamic dimension of the BHBIS: the expected results, that have been not fully achieved yet. There are many studies that stress a critical diagnosis of the BHBIS (Cassiolato et al. 2011 . Marques & Gonçalves Neto 2007 . Rezaie et al. 2008 . The critical remarks are mainly related to the micro and meso dimensions of Brazilian system, such as regulation and management innovation dimensions. In addition, some authors stressed the disappointment of firm's managers with some public programs that show an academic research bias (Barbosa et al. 2007 ).
In this sense, several agents stressed the relative low private sector development and to the gap between research capabilities and innovation results. Actually, this is one of the patterns that characterize the biotech development in the peripheral countries is the major strength in the phase of generation of knowledge -research and discovery-rather than in product development and commercialization (Quach et al. 2006) . In this general frame, SMEs entrance in the market is relatively easy -through science-push strategies-, but then they found strong difficulties to achieve and conserve a market position as final or intermediate product suppliers.
THE BOUNDARIES OF POLICIES
The stylized facts of the BHBIS presented in this paper show many of the goals pursued by public policies during the last decade. To understand the evolution of the policies and their rationale it is relevant considering that any policy is a deliberate effort to impact on economics and society which may confront with several problems through its implementation which, in turn, limit their effectiveness and potentially undermine its legitimacy (Giesecke 2000) .
The limits that the Brazilian health biotechnology policy confronts can be analyzed considering two main dimensions related to the evolution of policies: i) the change of policy orientation and rationale, ii) that pose new governance's challenges, which, in turn require new coordination with other implicit policies.
Even though the evolution of public policies between 2004 and 2014 has been erratic and even uneven, there is a significant change in the rationale of policies. This change, involve a complex transformation on the policy rational that only was partially presented in this paper. Dealing with complexity require high capabilities and more fluent governance resources.
The governance's problems are related to the basic features of biotechnology. Since it is a technology area rather than a economy sector, health biotechnology cannot be pigeonholed in the classical sectoral government structure, for instance, in only a sectoral ministry. It is not a problem, it is mostly a challenge; and probably it is not a new one. Coordination difficulties are as old as the public policy. Nevertheless, it establishes a serious limit to the effectiveness of policies.
Regarding the BHBIS, public governance have to deal with sectoral goals organized in an horizontal manner, mainly to coordinate with the implicit policies of the Healthcare System. Arguably, one of the more relevant aspects regarding public policy effectiveness is related to its coherence with other policies. Recent effort have been focused on health technological public procurement and public private partnership that include pre-commercial public procurement commitment.
Governance problems, basic resource and the articulation of different policies are undoubtedly very important to understand the effectiveness of the policies. However, the real limits of the policies are established by the behavior and preferences of the economic agents, specifically by the firms' behavior. Every policy documents begin with a chapter which exposes the motives that justify the initiative. All of them make -implicit or explicit-reference to the general interest and their relationship with individual benefits, and all of them try to change some kind of organization or behavior in order to pursue the general interest. Obviously, it is very difficult to agree about what the general interest is, and even more complicated is to agree on how to achieve it.
As is well known, policies are based on several assumptions about the agent behavior. The limit of the policies exists because -fortunately-the policies cannot impose rigid rules to the behavior's agent. Then, they can propose incentives to promote or inhibit determined actions.
It is probable that the great difficulties resulting from the combination of social, innovation and industrial policies in a technical environment in permanent change, would lead to new changes In 
